Kadcyla (ado-trastuzumab emtansine)
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
July 2016
USE IN SPECIFIC POPULATIONS
Hepatic Impairment (revised)
No adjustment to the starting dose is required for patients...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts
More News: Drugs & Pharmacology | Herceptin